Novo Nordisk Inc. issued the following announcement on Feb. 5.
Novo Nordisk today announced the availability of two new diabetes medications, Ozempic® (semaglutide) injection 0.5 mg or 1 mg and Fiasp® (insulin aspart injection) 100 Units/mL at pharmacies across the United States.
Ozempic® is a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.1
Fiasp® is a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.2
Both medications received approval from the U.S. Food and Drug Administration (FDA) in 2017 and represent the latest advancements to Novo Nordisk's robust diabetes portfolio.
"With 1.5 million new patients diagnosed with diabetes each year,3 we must continue to innovate and bring to market new options to meet the diverse needs of patients," said David Moore, senior vice president, Commercial, Novo Nordisk. "There is no one-size-fits-all approach to effectively managing diabetes and we are proud to add Ozempic® and Fiasp® to our market-leading portfolio to give patients new treatment options. Our robust portfolio of diabetes products addresses the concerns and needs of people with diabetes, particularly around dosing and administration."
Ozempic® is administered once weekly. In clinical trials, Ozempic® demonstrated statistically significant A1C reductions. Ozempic® is priced at parity to current market-leading weekly GLP-1 receptor agonists, and eligible patients with commercial insurance can use the Ozempic® Instant Savings Card to reduce co-pays to as low as $25 per prescription fill for up to two years. For more information about the instant savings card, please visit www.OzempicSavings.com or call 877-304-6855. Please visit www.ozempic.com for more information about Ozempic®.
Fiasp® is the first fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation. Fiasp® should be administered at the beginning of a meal or within 20 minutes after starting a meal due to its appearance in the blood in approximately 2.5 minutes.2 The list price of Fiasp® is the same as mealtime insulin NovoLog® and eligible patients with commercial insurance can use the Novo Nordisk Instant Savings Card to reduce co-pays for Fiasp® to as low as $25 per 30-day supply for up to two years. For more information about the instant savings card, please visit www.MyFiaspSavings.com or call 877-304-6852. Fiasp® is also available to eligible patients through the Novo Nordisk Patient Assistance Program. More information on the Novo Nordisk Patient Assistance Program is available by calling 866-310-7549. Please visit www.MyFiasp.com for more information about Fiasp®.
Original source can be found here.